Diamond Hill Capital Management LLC Investment Advisor Buys New Stake in Humana Inc. $HUM

Diamond Hill Capital Management LLC Investment Advisor purchased a new position in shares of Humana Inc. (NYSE:HUM) in the second quarter, HoldingsChannel reports. The institutional investor purchased 618,185 shares of the insurance provider’s stock, valued at approximately $245,555,000. Humana accounts for 2.0% of Diamond Hill Capital Management LLC Investment Advisor’s portfolio, making the stock its 11th largest position.

Other hedge funds also recently added to or reduced their stakes in the company. Wilkerson Advisory Group LLC lifted its stake in shares of Humana by 24.6% during the second quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider’s stock worth $66,000 after purchasing an additional 33 shares in the last quarter. Bogart Wealth LLC grew its stake in shares of Humana by 192.0% in the second quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider’s stock valued at $29,000 after buying an additional 48 shares in the last quarter. Fiduciary Alliance LLC raised its holdings in shares of Humana by 0.9% during the 1st quarter. Fiduciary Alliance LLC now owns 5,628 shares of the insurance provider’s stock valued at $976,000 after buying an additional 49 shares during the period. Sanctuary Advisors LLC raised its holdings in shares of Humana by 1.6% during the 4th quarter. Sanctuary Advisors LLC now owns 3,389 shares of the insurance provider’s stock valued at $868,000 after buying an additional 52 shares during the period. Finally, Horizon Investments LLC lifted its position in Humana by 2.5% during the 4th quarter. Horizon Investments LLC now owns 2,236 shares of the insurance provider’s stock worth $573,000 after acquiring an additional 55 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

HUM opened at $388.16 on Monday. The company has a market capitalization of $46.61 billion, a P/E ratio of 36.72, a PEG ratio of 2.23 and a beta of 0.72. The company has a 50-day moving average of $382.02 and a 200-day moving average of $275.76. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.74 and a current ratio of 1.74. Humana Inc. has a 1-year low of $163.11 and a 1-year high of $428.88.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping the consensus estimate of $7.27 by $0.34. The business had revenue of $40.89 billion for the quarter, compared to analysts’ expectations of $40.58 billion. Humana had a net margin of 0.88% and a return on equity of 11.20%. The company’s quarterly revenue was up 26.2% compared to the same quarter last year. During the same quarter last year, the company posted $6.27 earnings per share. Equities analysts expect that Humana Inc. will post 9.08 EPS for the current fiscal year.

Analyst Ratings Changes

HUM has been the subject of a number of analyst reports. Royal Bank Of Canada upped their price target on Humana from $246.00 to $415.00 and gave the stock a “sector perform” rating in a report on Thursday, July 9th. Sanford C. Bernstein reiterated an “outperform” rating and set a $425.00 price objective on shares of Humana in a research note on Wednesday, June 3rd. Barclays boosted their target price on shares of Humana from $344.00 to $407.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Wolfe Research upgraded shares of Humana from a “peer perform” rating to an “outperform” rating in a research note on Thursday, July 30th. Finally, William Blair began coverage on shares of Humana in a report on Wednesday, May 20th. They set an “outperform” rating for the company. Fourteen investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $395.22.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Zacks Research raised its Humana Q1 2028 EPS forecast to $11.53 from $8.58, Q2 2027 EPS to $5.27 from $4.20, and FY2028 EPS to $30.30 from $22.28. These revisions point to stronger anticipated profitability beyond the company’s near-term earnings pressures, although Zacks still rates the shares “Hold.”
• Positive Sentiment: Humana’s partnership with Cityblock Health will support low-income, dual-eligible Medicare Advantage members. The initiative could improve care coordination and outcomes while strengthening Humana’s position in Medicaid and Medicare-related markets. Humana teams with Cityblock to support dual eligible, MA low income members
• Positive Sentiment: A HealthStream agreement will fund 1,000 caregiver scholarships and provide recruiting and retention tools in Indiana. Better staffing could support Humana’s CenterWell and care-delivery operations over time. Can Humana Improve Caregiver Retention With HealthStream Deal?
• Neutral Sentiment: Humana agreed not to reference Teva’s Israeli ties during an upcoming drug price-fixing trial. The agreement avoids a potential courtroom distraction, but it does not materially change Humana’s operating outlook. Humana agrees not to reference Teva’s Israel ties at US drug trial
• Negative Sentiment: Zacks downgraded Humana from “Strong Buy” to “Hold” and reduced several forecasts, including Q3 2026 EPS from $0.08 to a loss of $1.18, Q4 2026 EPS to a loss of $7.74, and FY2027 EPS to $10.98 from $13.30. The revisions signal meaningful near-term earnings volatility.
• Negative Sentiment: Reports that Humana will exit markets affecting roughly 600,000 Medicare Advantage members in 2027 raise concerns about membership growth and future revenue, even if the moves are intended to improve plan profitability. Humana Medicare Advantage membership changes

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.